India mulls legal action against US think tank's 'smear' campaign
This article was originally published in Scrip
Executive Summary
Even as India's Prime Minister Narendra Modi is set to begin his high profile five-day visit to the US showcasing the country's best side to top global investors, senior government officials were engaged in a major fire-fighting exercise over allegations against the quality of medicines from India.
You may also be interested in...
Obituary: Indian Generics Industry Torchbearer Dilip Shah
Indian industry veteran and secretary general of the Indian Pharmaceutical Alliance, Dilip Shah, has died aged 77. Shah, a former commercial director of Pfizer in India, played a pivotal role in ensuring that the Indian generic industry's voice was heard.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet